Dr John Maher is a clinically active consultant immunologist at Eastbourne Hospital and King’s Health Partners. While a visiting fellow in the laboratory of Michel Sadelain, he was the first to engineer and test second generation CAR-T technology in human T cells, building on the pioneering work of Helene Finney in the Jurkat model system. He established CAR T-cell research at King’s College London in 2004 where he leads the "CAR Mechanics" group, which is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T cells. He is chief investigator of a Phase I clinical trial in which a pan-ErbB targeted CAR-T that he developed is being evaluated in patients with refractory locally advanced/ recurrent head and neck cancer.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Leucid Bio | Co-Founder & Chief Scientific Officer | Dec 1, 2014 | — | Detail |